アーディ・バイオサイエンシズ・インク | 10-Q：Q3 2024 四半期報告書

SEC11/07 05:14

Aadi Bioscience Remains Actively Engaged In A Comprehensive Strategic Review To Maximize Shareholder Value

Benzinga11/06 21:05

Aadi Bioscience Is Completing Wind-down Of PRECISION1 Trial Of Nab-sirolimus In Patients With Solid Tumors Harboring TSC1 Or TSC2 Inactivating Alterations

Benzinga11/06 21:04

Aadi Bioscience GAAP EPS of -$0.46 In-line, Revenue of $7.21M Beats by $0.61M

Seeking Alpha11/06 21:03

Aadi Bioscience 3Q Loss/Shr 46c >AADI

Dow Jones11/06 21:03

Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $7.2M

MT Newswires11/06 21:01